Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

NCT01354457 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: Epratuzumab and 90Y-Epratuzumab

Sponsor

Nantes University Hospital